埃博拉病毒,抗病毒药物 z-bo 2020-09-17 351

　　The most important event in the world of medicine and health this year is the Ebola outbreak in West Africa. This epidemic caused thousands of deaths of patients. This epidemic has also forced the biomedical industry and governments around the world to start to face the fact that there is a gap in the current Ebola virus treatment.

　　Recently, researchers announced that two promising drugs for the treatment of Ebola virus are about to enter the clinical research phase. The two drugs are Chimerix's brincidofovir and Fujifilm's favipiravir. According to the estimates of the researchers, these studies will be launched as soon as next month. If all goes well, the researchers will get preliminary results in February 2015. And this speed also benefits from the emergency review mechanism of the relevant medical management departments for this research.

　　Oxford University will lead the clinical research of brincidofovir, and the French National Health Center will lead the clinical research of favipiravir. The Antwerp Institute of Tropical Medicine in Belgium will also conduct research on treatment options for Ebola patients during the recovery period.

　　Relevant people said that these three research projects will help to find the best treatment for Ebola virus in a short period of time and explore a combination of treatment options for this disease.

　　Fujifilm's favipiravir mainly inhibits virus proliferation by blocking viral nucleic acid replication. In the battle against the Ebola epidemic this year, this drug was urgently used to treat Ebola patients and achieved good results. At present, favipiravir has been approved for marketing in Japan, and there is also a study in the United States for the treatment of influenza that is in the phase III clinical research phase. And Chimerix's brincidofovir has shined in this year's Ebola epidemic. In recent months, Chimerix is conducting a Phase II clinical study of brincidofovir for the treatment of Ebola, which recruited 50 Ebola patients. Prior to this, Chimerix CEO Michelle Berrey had specifically contacted the FDA to discuss the possibility of accelerating brincidofovir research.